• MONI is an investment company focusing on acquisitions in the fintech, crypto, precious metals, and real estate sectors
• MONI reveals its participation in the annual SALT Conference, one of the world’s premier hedge fund events held in New York between September 13-15, 2021
• In addition to their marketing efforts, MONI is actively expanding their business – including the acquisition of mining company, Royal Costino LLC, and the development of their cryptocurrency business

Moon Equity Holdings (OTC: MONI) is an investment company focusing on acquisitions in fintech, crypto, precious metals, and real estate sectors. The company has centered its business philosophy around providing shareholders with a well-diversified acquisition portfolio focused on income-generating strategies that produce long-term gains. MONI’s management recently revealed that they would be attending the SALT Conference held at New York’s Jacob K. Javits Convention Center between September 13-15, 2021. The SALT event, one of the premier hedge fund conferences, has long gained a reputation as one of the globe’s most prominent thought leadership and networking forums in finance, technology, and geopolitics. Their goal is to connect leading asset managers and entrepreneurs to some of the world’s top asset owners, investment advisors, and policy experts. This year’s event features approximately 2,300 attendees alongside a series of influential speakers, including Brooklyn Borough President Eric Adams, the leading candidate in New York’s mayoral race, and prominent investors like Steven A. Cohen, Daniel Loeb, Ray Dalio, Marc Lasry, and Mike Novogratz. Moreover, the conference was also set to feature a series of enlightening panel discussions on cryptocurrency trading, post-pandemic best ideas, and geopolitics (https://ibn.fm/vzRtZ). “Our goal has always been to empower big, important ideas and foster a community to address shared challenges,” stated Anthony Scaramucci, founder of SkyBridge Capital and chief organizer of the SALT Conference. “We’re also bringing SALT to NYC for the first time to help spur revitalization efforts in the city, and want to demonstrate leadership by returning to some semblance of normalcy while maintaining a safe environment for our attendees.” MONI has recently undertaken a spate of corporate actions designed to influence its business model going forward. Earlier this year, the company acquired Royal Costino LLC as a wholly-owned subsidiary for its newly created mining division. The acquisition is the first step for the company in two planned mining acquisitions this year, with the Royal Costino deal expected to generate an estimated $2 million per month in additional income for the company (https://ibn.fm/Z97GB). The company has been developing a crypto component alongside two proprietary applications designed to revolutionize how individuals gift and purchase cryptocurrency. Through their venture into the digital currency space, Moon Equity Holdings expect to enhance their customer experience, thereby creating a loyal brand following and generating repeat business. For more information, visit the company’s website at www.MoonEquityHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to MONI are available in the company’s newsroom at https://ibn.fm/MONI

• The company has completed many milestones to date, with plans to finalize its Phase 2 Hydrogen-Ammonia Synthesizer commercial prototype by the end of 2021, and other high-visibility projects planned for 2022
• Hydrogen transportation and storage poses a problem on account of volatility and high costs, but carbon-free ammonia is a cost-efficient and environmentally logical alternative
• The weather of 2021 has been a key indicator of the climate changes that are taking place and the need to work toward the net-zero 2050 plans made globally

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a growth-stage company focused on providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (“NH3”), for use across a broad spectrum of industries and applications, has provided a corporate update announcing that prototype development milestones have been set and met (https://ibn.fm/6WpPj). The company’s lead technology is a system for producing carbon-free ammonia for use across various industries and applications. FuelPositive recently presented at the H.C. Wainwright 23rd Annual Global Investment Conference, where CEO and Board Chair Ian Clifford participated in one-on-one meetings. The company presented its most recent corporate presentation during the conference and also announced that prototype systems are scheduled for completion by the end of 2021, and that high-visibility projects are planned for 2022. “Having received extensive interest from investors and potential partners since our last corporate update on July 15, we felt it would be helpful to share how we are progressing, particularly regarding the building of our Phase 2 Hydrogen-Ammonia Synthesizer commercial prototype systems,” Clifford explained in the corporate update. To date, the milestones met by FuelPositive include:

• Process Determination – establishment of the flow diagram, process map completed, and major component design parameters have been established
• Major Component Vendor Selection and Procurement – the production of hydrogen, nitrogen, fabrication of reactors, separation process, and heat exchangers
• Engineering Design – process modeling and design, reactor modeling and design, ammonia separation modeling and design, and instrumentation and control process development and design

Interested in the effects of climate change and the impact of fossil fuels on the environment, FuelPositive sees the changes that have taken place within this category. One of the most common signs that complex systems are reaching a tipping point is the rise in volatility. An example is the extreme weather patterns of 2021 – heat domes, droughts, fires, floods, cyclones, and more. Because of these increasingly alarming patterns, much of the world is adopting plans for climate action, with a goal of net-zero by 2050. And, as it says in a recent article, “…But net zero commitments by other sectors work only if farmland goes sharply net negative. That means an end to livestock farming and the restoration of forests, peat bogs and other natural carbon sinks.” (https://ibn.fm/seNdc). With many industries looking at hydrogen as a potential replacement for current fuel measures, it is still undeniable that clean hydrogen may be too expensive and inefficient to play a major role in the decarbonization of heat, transport, and heavy industries (https://ibn.fm/AOrtx). Hydrogen is extremely difficult and energy intensive. The end product is highly volatile, essentially difficult to contain, making it an inappropriate option as an energy carrier. FuelPositive’s carbon-free ammonia offers a solution to this problem. Carbon-free ammonia is more cost-effective and easily contained, and can be used either as a clean hydrogen carrier or a fueling method per se. The company’s patent-pending first-of-its-kind carbon-free ammonia has the potential to eliminate and replace fossil fuels in several industries, including agriculture and transportation, reduce the need for massive ammonia processing facilities, produce carbon credits on a substantial level, help provide electricity for grid storage and fuel the shift to a hydrogen economy. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Health diagnostics technology innovator Avricore Health has introduced its HealthTab platform as a means of improving patients’ ability to monitor their health conditions through point-of-care testing under the guidance of trained pharmacists
• HealthTab uses partnerships with molecular testing device makers to establish rapid molecular testing services in pharmacies, including the Shoppers Drug Mart pharmacy network in Ontario
• The initial rollout has taken place in 15 Shoppers pharmacies, with rapid scaling planned to achieve more than 600 locations by the end of 2023
• HealthTab’s diagnostics platform is designed to be high quality with appropriate approvals and certifications, helping patients to avoid delays in lab result turnaround
• The COVID pandemic has exposed weaknesses in lab result turnaround time capacity, but Avricore’s testing offers solutions that include COVID infection analysis under a new agreement

The unexpected advent of the COVID-19 global pandemic last year taxed health response infrastructures on numerous fronts as the rapidly spreading SARS-COV-2 virus caused an influx of sick and dying patients at hospitals struggling to keep up with demands for intensive care. The health emergency exposed weaknesses in the diagnostic ecosystem, as well. Once testing protocols were developed, health experts still struggled to get labs the necessary resources and labs struggled to turn around test results in a timely fashion (https://ibn.fm/gdfiR). By November, many labs were reporting they had improved turnaround times for COVID results to one-to-two days, but as case numbers began a winter surge in the United States and the Centers for Medicare and Medicaid Services (“CMS”) threatened to cut its payments to slow labs, lab professionals braced for new obstacles to timely reporting (https://ibn.fm/ppGHh). Those challenges persist, particularly affected by the ebb and flow of COVID case rates during the current pandemic climate. The Baltimore Sun reported this month that a new increase in test demand as COVID infections rise and a variety of business and government institutions mandate testing is again threatening turnaround times and may, as a result, create an unintended increase in outbreaks if those left waiting for lab results fail to quarantine (https://ibn.fm/5a56Q). Pharmacy services developer Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is helping to tackle the problem head-on with the rollout of its Point of Care Testing ecosystem that encourages patients to get lab-quality results for COVID and other illnesses at local pharmacies, with the results then shared seamlessly to patients, medical professionals and researchers in real time without compromising health privacy. Avricore’s flagship HealthTab platform establishes the interlocking data connections, drawing on partnerships with Abbott Diagnostics and Abaxis Global Diagnostics for the technological interfaces that are lab-grade instruments compliant with U.S. Food and Drug Administration (“FDA”) and European Conformitè Europëenne (“CE”) standards and Clinical Laboratory Improvement Amendments (“CLIA”) certification (https://ibn.fm/HE5Ei). Abbott’s trademarked ID Now molecular testing instrument is capable of a molecular test for COVID-19, as well as other common infectious respiratory illness pharmacies treat, such as Respiratory Syncytial Virus (“RSV”), influenza A and B, and strep.  This allows pharmacies to identify, treat share information quickly and accurately with respect to these illnesses, add to the company’s trademarked Afinion 2 device for testing for heart disease and diabetes data in use through HealthTab (https://ibn.fm/ftWiG). “With ID Now(TM) on the HealthTab(TM) network in community pharmacy, patients can know what they have and get focused treatment and prevent spread through better information,” Avricore CEO Hector Bremner stated in the company’s announcement about the device. HealthTab’s initial rollout has taken place on a limited basis through the Shoppers Drug Mart pharmacy network based in Ontario, Canada, with the simple blood-testing protocol under a trained pharmacist’s guidance available in 15 stores (https://ibn.fm/janUn). The company plans to quickly expand its pharmacy location buildout to 600 stores by late 2023 with EBITDA pushing profits into the positive territory by next summer (https://ibn.fm/WoSFc). The ultimate aim of Avricore’s services is to increase patients’ wellness, with better awareness leading to better care and better care producing better outcomes. On Sept. 13, Avricore announced it has retained Oak Hill Financial Services Inc. to provide services such as drafting marketing materials and increasing Avricore’s visibility through Oak Hill’s Canadian investor network. “We are really excited by Oak Hill’s track record of success in our sector, and they share our passion for the mission behind our core business. I’m confident in their team’s abilities to help us achieve our market-based goals,” Bremner stated (https://ibn.fm/3BBDY). For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Dozy Mmobuosi, CEO and co-founder of Tingo Mobile, aims to accelerate digital commerce in Agritech and Fintech verticals across Africa
• Mmobuosi spearheaded the design and launch of Nigeria’s first SMS banking solution and has led Tingo’s growth to more than $600 million in annual revenue
• Tingo’s innovative mobile Agritech and Fintech platforms and credit solutions bolster commerce, connect markets and provide mobile banking services
• Due to growing need and demand, Mmobuosi expects Tingo Mobile to become the continent’s leading Agri-Fintech business powered through smartphone technology

Dozy Mmobuosi founded Tingo Mobile in 2001 to bring mobile technology and Fintech solutions to the unbanked rural areas in Nigeria. Mmobousi’s first Fintech endeavor was a revolutionary SMS banking solution which represented the first mobile payment platform in Nigeria which remains in use today. Mmobuosi’s entrepreneurial spirit was evident even in his youth when he was threatened with expulsion for selling “provision commodities” while in secondary school in Nigeria. He even cleaned and packaged used clothing for re-sale while home on holiday. From those humble beginnings he began to promote concerts and events and eventually created, Naijafans, the only Nigerian-focused social media platform at the time. Along the way he managed to earn advanced degrees, holding a Bachelor of Science and Master of Science degrees in political science and economics, respectively, from Ambrose Alli University in Ekpoma, and a Ph.D. in rural advancement from Universiti Putra Malaysia. Fast forward a few decades, and Mmobuosi, now 43, has brought his company, Tingo (OTCQB: IWBB), public in a deal valued at $3.7 billion. Tingo, with over $600 million annual revenues and nearly 10 million subscribers, is Nigeria’s leading Agri-Fintech and device-as-a-service platform aimed at accelerating digital commerce in the agricultural sector. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Mmobuosi headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, to produce and distribute 20 million phones across the country. Tingo connects farmers to markets, services and resources via Nwassa, its digital Agritech marketplace platform that commenced operations in 2020. More recently, Mmobuosi directed the launch of a beta version of TingoPay – a B2B and B2C fintech app which will provide financial services to users inside and outside of agriculture which includes mobile wallets, payment processing and access to specialist lenders, insurers and pension products. Mmobuosi also plans for Tingo to soon roll out a blockchain-based solution that will empower frictionless trade across borders in Africa. This innovation and market-proven model give Tingo the ability to deliver the same service model across all of Africa and transform the continent with Agri-Fintech solutions powered through smartphone technology. Tingo intends to become a truly Pan-African company with global reach that modernizes the continent by providing a complete digital ecosystem to facilitate financial interaction and deliver disruptive micro-finance solutions. Digitally connecting the agricultural value chain that represents such a large share of Africa’s economy could easily be the impetus to democratizing commerce and propelling the continent into the 21st century. Through Tingo Inc., Dozy Mmobuosi is committed to delivering Agri-Fintech, telecommunications and market access to millions of farmers, consumers and other key players across Africa. A marketplace platform that connects every stakeholder in the agricultural value chain, from farmers, to packaging and logistic partners to everyday people looking to purchase fresh produce at the best prices is certain to change the fortunes of Africa, one of the last frontiers for global growth. For more information, visit the company’s website at www.TingoGroup.com. NOTE TO INVESTORS: The latest news and updates relating to IWBB are available in the company’s newsroom at https://ibn.fm/IWBB

• States that have already legalized cannabis are seeing a spike in business thanks to the overwhelming convenience of cannabis delivery
• Article reports that delivery services can “help surge revenue for retailers that jump in to take advantage”
• Earlier this year, SGMD launched a new business initiative for the licensed delivery of cannabis products

According to a recent article, states that have already legalized cannabis, such as California, are seeing a spike in business thanks to the overwhelming convenience of cannabis delivery (https://ibn.fm/AGyL4). This is great news for Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis scene with majority control and ownership of cannabis delivery service Nug Avenue, based in Southern California and providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay, Cookies and more. “Just in January of 2019, California legalized statewide cannabis delivery,” noted the article, titled “The Hottest Revenue Stream in Cannabis” and released by High There, the largest cannabis social network. “This removed the previous regulations that prevented the legal access to cannabis delivery throughout roughly 70% of the state. . . . As of January 19, cannabis delivery services can reach almost any address in California – and this includes the areas where retailers are still banned from opening a storefront. “Landmark states that have already legalized cannabis, like California, are seeing a spike in business thanks to the overwhelming convenience of cannabis delivery,” the article continued. “Since January 19, the promise for delivery being the next wave in cannabis commerce is becoming obvious.  What many are considering the next trend for cannabis business, delivery services can help surge revenue for the retailers that jump in to take advantage.” The article noted that the cannabis industry is already a record $10 billion and climbing, even with cannabis prohibition still in place in much of the country.  “A particularly explosive section of this industry is almost exclusively the new cannabis delivery sector,” the article stated. “In fact, according to Statista.com, 44% of medical marijuana users across the U.S. regularly used a cannabis delivery service to buy their bud.  With legalization only having ramped up since then, it’s likely the numbers have only continued to increase, making the market ripe for cannabis delivery.” Earlier this year, Sugarmade acquired a 70% stake in Nug Avenue, a Lynwood, California-based cannabis delivery operation, and launched a new business initiative for the licensed delivery of cannabis products (https://ibn.fm/Yn6Jj). “We strongly believe the LA delivery market is the prime spot for expansion of our business,” said Sugarmade CEO Jimmy Chan.  “California is the world’s sixth-largest economy, and LA County is by far the most significant driver, with over 25% of the state’s population.  The Lynwood, California, site is optimal, as it is located along one of the major distribution freeways, allowing drivers to efficiently reach the more than 15 million consumers that live within a 30-mile radius of the new location. We plan to make a big impact on the LA cannabis delivery marketplace.” Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes NUG Avenue, CarryOutsupplies.com and SugarRush. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• FuelPositive announced four new appointments – Nelson Leite and Olushola Ashiru have joined the Board, while Francois Desloges and Jennifer Spencer have been appointed to the Executive Leadership Team
• The appointments are in a move to actualize Phase Two of the company’s Hydrogen-Ammonia Synthesizer commercial prototype system, critical to its future growth
• FuelPositive’s CEO expressed enthusiasm with the new appointments, citing that they will be integral to the company’s plans for creating and developing technologies and solutions to fight climate change
• The company’s CEO also appeared on the Gamechangers LIVE podcast, where he shared his personal story, background, mindset, struggles and the future of FuelPositive

On September 13, 2021, FuelPositive (TSX.V NHHH) (OTCQB: NHHHF) provided a corporate update, specifically on the development of its Phase 2 Hydrogen-Ammonia Synthesizer commercial prototype system. In the update, the company noted that the successful building of the prototype systems will confirm the broad application potential for the company’s carbon-free NH3 technology, which will be a massive milestone for FuelPositive (https://ibn.fm/l4pYW). To guide it through this second phase of its growth plans, FuelPositive earlier announced key appointments to its Board of Directors and management team. While publicizing the selections, Ian Clifford, the Chief Executive Officer (“CEO”) and Chair of the Board, acknowledged that FuelPositive is no longer solely an R&D company. Instead, he noted that it is an enterprise that is seeking to ensure the excellence of its work as it commercializes its lead technology – carbon-free ammonia (“NH3”) (https://ibn.fm/uLxFs). Nelson Leite was appointed as the company’s new Chief Operating Officer (“COO”) and member of the Board of Directors. Mr. Leite brings decades of experience in robotics and manufacturing automation, which will benefit the company as it advances its breakthrough NH3 technology. When making the announcement, Mr. Clifford noted: “The team and I are thrilled to have Nelson join us at this pivotal time. He brings decades of experience in the most sophisticated manufacturing processes and disciplines to the company, right at the time that we are advancing our breakthrough carbon-free NH3 technology. Nelson also cares deeply about the importance of our work related to eliminating carbon emissions.” The company also appointed Olushola (Shola) Ashiru, who will serve on the Board of Directors as an Independent Director. Shola will lend her knowledge of the clean technologies sector and capital markets to the company, allowing it to develop its core technology further and plan its future, creating and developing technologies and solutions to fight climate change. Other additions to the FuelPositive team included Francois Desloges, who will serve as Senior Research Scientist, and Jennifer Spencer, who will work as the Director of Communications. Mr. Leite and Ms. Ashiru will be granted an aggregate of 3,500,000 incentive stock options at $0.185 until September 8, 2026. The options will vest over 18 months, with one-quarter vesting immediately and a further quarter vesting every six months after that. FuelPositive also announced that Greg Gooch will be retiring as President and Board Member of the enterprise, although he will remain involved as a Strategic Advisor to the company. “Greg has contributed heavily to FuelPositive, providing much-valued guidance as we navigated the early days as a Company. We all wish him well in this new phase of his life,” noted Mr. Clifford. Mr. Clifford also recently appeared on Gamechangers LIVE, a podcast series that highlights individuals who are game-changers in their respective fields (https://ibn.fm/rLfsE). The podcast is usually a platform where these individuals share their journeys, experiences, struggles, mindsets and successes to inform and inspire listeners. In the interview, Mr. Clifford talked about his background in landscape photography, assisting Ansel Adam’s at the young age of 18, and how that immediately grew into a lifelong connection to environmentalism. He also spoke about how his life journey led to him to creating FuelPositive with an amazing team of like-minded people, committed to introducing and commercializing technology related to carbon-free NH3. Mr. Clifford was also keen to explain the significance of carbon-free ammonia as a breakthrough molecule, as well as the environmental and practical benefits of FuelPositive’s modular, scalable, carbon-free ammonia production systems for a broad range of industries. The podcast, which was hosted by Sergio Tigera, an Executive Coach and Speaker, can be accessed via this link: https://ibn.fm/mfL2d For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Nemaura’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed for people with diabetes and prediabetes
• sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDA
• Nemaura continues to build a world-class management team
• Nemaura plans to launch a direct to consumer metabolic health program in 2021, using its glucose monitoring platform at the core of the program
• Nemaura has several patents (both filed and pending) and substantial trade secrets covering its technology platform
• The company has orders in the U.K. for 200,000 sugarBEAT sensors and a further 2 million projected over the next two years for the U.K. alone
• The company is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (“PMA”) application to the U.S. Food and Drug Administration in 2020 which is currently under review. Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring. Technologies Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes. Glucose Monitoring Solutions for Diabetes Prevention and Reversal Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management. Continuous Lactate Monitoring for Athletic Performance (Non-Medical) Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (“ATP”). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022. Continuous Lactate Monitoring in Disease State (Medical) An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies. Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022. Market Opportunity Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk. On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023. Management Team Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery. Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP. Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip(R), the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany. David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing. For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc.
• BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoids
• Upon closing, the transaction will make InMed a global leader in the manufacturing of rare cannabinoids in addition to transforming it into a revenue-generating company
• Acquisition provides InMed with the complete flexibility across multiple manufacturing approaches

On September 13, InMed Pharmaceuticals (NASDAQ: INM), a company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced it has signed a definitive agreement to acquire 100% of BayMedica Inc., a US-based private company that specializes in the manufacture and commercialization of rare cannabinoids, in a stock-based transaction expected to close in the coming weeks, subject to various customary closing conditions (https://ibn.fm/ckdlh). Upon closing, the transaction will cement a relationship that began in late 2020 when InMed and BayMedica announced they had entered into a broad collaborative research agreement (https://ibn.fm/dpuuO). Under the terms of the 2020 agreement, InMed would undertake the preclinical investigation of multiple therapeutic compounds selected from BayMedica’s extensive library of proprietary cannabinoid analogs in addition to exploring the therapeutic potential of specific analog compounds in selected disease models. On its part, BayMedica would be given access to particular elements of IntegraSyn(TM), InMed’s proprietary platform for producing cannabinoids using novel proprietary enzyme(s), in order to assess the potential of one or more of InMed’s high-efficiency enzyme sequences in BayMedica’s systems for the production of cannabinoids in BayMedica’s catalog. This collaboration led to an announcement, issued June 29 this year, that InMed had entered into a non-binding letter of intent (“LOI”) to acquire 100% of BayMedica (https://ibn.fm/PBV55). At the time, InMed’s President and CEO, Eric A. Adams, noted that the existing collaboration had made it apparent that the two companies’ business models and capabilities could provide a platform to expedite their growth, as well as provide flexibility of multiple processes for the manufacturing of rare cannabinoids. “We believe that IntegraSyn, our pharmaceutical-grade manufacturing process, together with BayMedica’s revenue-generating, consumer-focused process, would create a powerful combination,” Adams added. Upon closing, the transaction, as detailed in the most recent announcement, will indeed create a powerful combination. It will make InMed a global leader in the manufacture of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s IntegraSyn combined with BayMedica’s synthetic biology and chemical synthesis capabilities will offer InMed the complete manufacturing flexibility to choose the most appropriate, cost-effective manufacturing method based on prevailing conditions. At the same time, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development. It will also increase commercial sales of rare cannabinoids to the consumer health and wellness sector. “This is a transformative transaction for InMed. The acquisition gives us a breadth of synthetic cannabinoid manufacturing capabilities to deliver high quality, cost-effective rare cannabinoids for any segment of the market from consumer packaged goods (‘CPG’) to prescription pharmaceuticals,” said Adams. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space.” Adams further noted that the transaction will transform InMed into a revenue-generating company, offering value to its shareholders. BayMedica commenced the sale of Prodiol(R) cannabichromene (“CBC”), its initial rare cannabinoid product, in December 2019. Since then, the sales revenues have grown steadily, with the cumulative figure currently exceeding $2.5 million. BayMedica also boasts an industry-leading batch production of CBC, the ability to expand the capacity as market demand increases, and multiple high-value non-intoxicating rare cannabinoids in various stages of commercial manufacturing scale-up. As part of the agreement, InMed will issue 1.78 million of its common shares to BayMedica’s equity and convertible debt holders; any such issued InMed common shares will be subject to a six-month contractual hold period. Notably, however, the total number of InMed common shares issuable in the proposed transaction may be reduced depending on the findings of a financial review of BayMedica’s closing balance sheet (go through the press release for a more detailed breakdown of the terms of the transaction). Eric Adams and BayMedica CEO Shane Johnson will offer more information about this transaction in an Edison Research-hosted webinar slated for Thursday, September 16, 2020, at 11:00 AM ET. Listeners should also expect to hear more about InMed’s future developments. To register for the webinar, please visit (https://ibn.fm/RqKhJ). For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate
• The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns
• Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan
• The DEA recently recommended a significant increase in cannabis and psilocybin use in medical science research, and the White House has asked Congress to consider changing drug legislation to better address the use of those drugs in clinical research

Two years after the U.S. Food and Drug Administration (“FDA”) declared the hallucinogenic substance psilocybin a “breakthrough therapy” to speed the process of the drug’s scientific clinical trials and reviews (https://ibn.fm/umfbQ), Michigan continues to cement its reputation as a hotbed for medicinal psychedelics advocacy and research, and proponents there believe society has reached a watershed moment for the substances’ acceptance. Law enforcement officials in the state’s Ann Arbor region have effectively decriminalized natural compounds with hallucinogenic properties deemed illegal under state and federal law (although not synthetic compounds such as LSD), and last month Ann Arbor’s City Council voted 10-0 to declare September “Entheogenic Plant and Fungi Awareness Month.” As a result, the city will celebrate a “sacred plant and mushroom festival” called Entheo Fest every September, beginning Sept. 19 (https://ibn.fm/1UXcX). The decisions highlight a growing cultural shift not unlike the transformation of cannabis’ stigma to a general acceptance of marijuana’s potential for therapeutic and recreational use when produced under quality constraints by recognized business enterprises in recent years. Earlier this month, the Drug Enforcement Administration (“DEA”) proposed a huge increase in the production of marijuana and psilocybin for research purposes with the hope of accelerating new federally approved therapeutic medications (https://ibn.fm/6t5FB). The White House then issued a set of recommendations to Congress asking lawmakers to consider addressing addiction worries and proposals for new clinical research involving marijuana and psychedelics by changing the way select hallucinogenic substances are regulated (https://ibn.fm/dWPuE). San Diego-based Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on novel bioscience solutions for medical conditions with unmet needs, specifically oriented toward developing its synthetic psilocybin candidates through clinical trials that target chronic pain and select eating disorders. The company expects to soon launch a Phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome (“PWS”), hypothalamic obesity eating disorder resulting from the removal of a brain tumor, and binge eating disorder. TRP-8802 will be used in combination with psychotherapy under professional care. “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders,” Dr. Jennifer Miller, the trial’s principal investigator, stated during an interview with The Dales Report in May (https://ibn.fm/7eX83). “Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the company added in a news release last month (https://ibn.fm/ljJmr). “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders”. Tryp Therapeutics then plans to proceed into Phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain barrier and effectively respond to pain and addiction concerns. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure
• Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant”
• Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop in systolic pressure
• These results bring Lexaria closer to NDA filing with the FDA, making it a pioneer in CBD hypertension treatment

Lexaria Bioscience (NASDAQ: LEXX) just released the most recent results from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure (“BP”) over a 24-hour ambulatory period. The results, referred to as “Statistically significant” by Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, inched the company closer to an eventual New Drug Application (“NDA”) (https://ibn.fm/pDUHy). The study involved volunteers getting three doses of 150 mg of DehydraTECH CBD over 24 hours, spanning both sleep and wake cycles of activity. Participants coping with mild to moderate hypertension reported up to an impressive average 23% decrease in blood pressure, relative to placebo, during the 24 hours. The study also showed that these individuals averaged a 7% drop in systolic pressure. Upon further analysis of the results, it was established that each of the three doses resulted in a slightly lower blood pressure level than the trough, which is usually the lowest concentration reached by a drug before the next dose is administered. This was mainly apparent during the quiet hours of sleep when most individuals are more prone to cardiac events. When making the announcement, Mr. Bunka noted: “Our 2018 study showed a slight reduction in blood pressure, but it was not awe-inspiring. This time, the average drop in blood pressure is larger, and it appears that the sequential doses are additive. We’ll investigate that further.” This clinical trial and the results from the study so far have prompted Lexaria into beginning an Investigational New Drug Application (“NDA”) filing with the FDA. The company plans to make the application, listing DehydraTECH CBD as a prospective registered pharmaceutical treatment for hypertension. DehydraTECH CBD is already patent granted in both the EU and in Australia, for treating heart disease. Going forward, Lexaria expects to stay consistent with its studies, with the hope of showing more positive results. The goal is to leverage both internal and external data on the effectiveness of DehydraTECH and even to possibly use the abbreviated 505(b)(2) NDA application to speed up timelines for approval. “If we can sustain these results, we could be looking at mega-drug status ($1 billion per year) in the hypertension market,” noted Mr. Bunka. “Our goal now is to put together a 4-week study, three doses per day, targeting a sustained drop in blood pressure. That could make us one of the most effective registered pharmaceutical treatments for hypertension in the world, with few if any unwanted side effects,” he added. Lexaria is currently focusing on undertaking the requisite procedures, having already established commercial success with its technology. Shareholders are optimistic about the company’s future, and for a good reason. The strides that Lexaria has made so far have brought it even closer to its DehydraTECH approval for hypertension treatment and management. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX